KR960016862B1 - 사람 인터루킨-4의 특정 잔기 서열로 이루어진 폴리펩타이드 및 이에 대한 항체의 제조방법 - Google Patents

사람 인터루킨-4의 특정 잔기 서열로 이루어진 폴리펩타이드 및 이에 대한 항체의 제조방법 Download PDF

Info

Publication number
KR960016862B1
KR960016862B1 KR1019920701458A KR920701458A KR960016862B1 KR 960016862 B1 KR960016862 B1 KR 960016862B1 KR 1019920701458 A KR1019920701458 A KR 1019920701458A KR 920701458 A KR920701458 A KR 920701458A KR 960016862 B1 KR960016862 B1 KR 960016862B1
Authority
KR
South Korea
Prior art keywords
polypeptide
amino acid
human
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920701458A
Other languages
English (en)
Korean (ko)
Other versions
KR920703642A (ko
Inventor
라마나탄 라타
에프. 시일릭 게일
피. 트로타 폴
Original Assignee
쉐링 코포레이션
제임스 알. 넬슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 코포레이션, 제임스 알. 넬슨 filed Critical 쉐링 코포레이션
Publication of KR920703642A publication Critical patent/KR920703642A/ko
Application granted granted Critical
Publication of KR960016862B1 publication Critical patent/KR960016862B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019920701458A 1989-12-20 1990-12-18 사람 인터루킨-4의 특정 잔기 서열로 이루어진 폴리펩타이드 및 이에 대한 항체의 제조방법 Expired - Fee Related KR960016862B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45357089A 1989-12-20 1989-12-20
US07/453,570 1989-12-20
US07/453570 1989-12-20
PCT/US1990/007289 WO1991009059A1 (en) 1989-12-20 1990-12-18 Antibody antagonists of human interleukin-4

Publications (2)

Publication Number Publication Date
KR920703642A KR920703642A (ko) 1992-12-18
KR960016862B1 true KR960016862B1 (ko) 1996-12-23

Family

ID=23801108

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701458A Expired - Fee Related KR960016862B1 (ko) 1989-12-20 1990-12-18 사람 인터루킨-4의 특정 잔기 서열로 이루어진 폴리펩타이드 및 이에 대한 항체의 제조방법

Country Status (26)

Country Link
US (1) US6358509B1 (https=)
EP (1) EP0506826B1 (https=)
JP (1) JPH0730116B2 (https=)
KR (1) KR960016862B1 (https=)
AT (1) ATE136906T1 (https=)
AU (1) AU639754B2 (https=)
CA (1) CA2071908C (https=)
CZ (1) CZ283050B6 (https=)
DE (1) DE69026627T2 (https=)
DK (1) DK0506826T3 (https=)
ES (1) ES2085983T3 (https=)
FI (1) FI104180B1 (https=)
GR (1) GR3020325T3 (https=)
HU (1) HU215245B (https=)
IE (1) IE74708B1 (https=)
IL (1) IL96714A0 (https=)
MX (1) MX9203401A (https=)
MY (1) MY106507A (https=)
NO (1) NO922457D0 (https=)
NZ (1) NZ236511A (https=)
OA (1) OA09704A (https=)
PT (1) PT96230B (https=)
SK (1) SK635290A3 (https=)
TW (1) TW221675B (https=)
WO (1) WO1991009059A1 (https=)
ZA (1) ZA9010190B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1995007301A1 (en) * 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
MXPA01006006A (es) 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
DE60135170D1 (de) * 2000-04-06 2008-09-18 Fujifilm Corp Farbstoffkomplex und optisches Informationsaufzeichnungsmedium
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
AU2003251633A1 (en) * 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
RU2382049C2 (ru) * 2004-08-03 2010-02-20 Новартис Аг ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ-4 (hIL-4)
NZ592943A (en) * 2008-11-17 2012-09-28 Uinv Kobenhavns Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2018108836A (ru) 2011-02-04 2019-03-14 Дженентек, Инк. ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
BR122021009041B1 (pt) 2014-05-06 2022-11-29 Genentech, Inc Métodos para a preparação de uma proteína heteromultimérica
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80678A (en) * 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
ZA872781B (en) 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
DE68908431T2 (de) * 1988-02-02 1993-12-23 Schering Biotech Corp Methode zur Verminderung der Immunglobulin-E-Reaktion.

Also Published As

Publication number Publication date
ZA9010190B (en) 1991-08-28
ES2085983T3 (es) 1996-06-16
MY106507A (en) 1995-06-30
HU215245B (hu) 1998-11-30
NO922457L (no) 1992-06-19
ATE136906T1 (de) 1996-05-15
SK279933B6 (sk) 1999-06-11
IE74708B1 (en) 1997-07-30
HU9202073D0 (en) 1992-09-28
CA2071908A1 (en) 1991-06-21
HUT64568A (en) 1994-01-28
FI922847A0 (fi) 1992-06-18
NZ236511A (en) 1993-02-25
GR3020325T3 (en) 1996-09-30
FI104180B (fi) 1999-11-30
MX9203401A (es) 1992-07-01
DE69026627D1 (de) 1996-05-23
PT96230B (pt) 1998-06-30
AU639754B2 (en) 1993-08-05
JPH04506359A (ja) 1992-11-05
FI104180B1 (fi) 1999-11-30
TW221675B (https=) 1994-03-11
CZ283050B6 (cs) 1997-12-17
CZ635290A3 (en) 1997-08-13
FI922847L (fi) 1992-06-18
CA2071908C (en) 2002-04-30
NO922457D0 (no) 1992-06-19
EP0506826B1 (en) 1996-04-17
IL96714A0 (en) 1991-09-16
JPH0730116B2 (ja) 1995-04-05
OA09704A (en) 1993-08-30
EP0506826A1 (en) 1992-10-07
IE904589A1 (en) 1991-07-03
SK635290A3 (en) 1999-06-11
AU7176291A (en) 1991-07-18
DK0506826T3 (da) 1996-05-13
US6358509B1 (en) 2002-03-19
WO1991009059A1 (en) 1991-06-27
DE69026627T2 (de) 1996-08-22
KR920703642A (ko) 1992-12-18
PT96230A (pt) 1991-10-15

Similar Documents

Publication Publication Date Title
KR960016862B1 (ko) 사람 인터루킨-4의 특정 잔기 서열로 이루어진 폴리펩타이드 및 이에 대한 항체의 제조방법
CA2021912C (en) Erythropoietin (epo) peptides and antibodies directed against these
US5013824A (en) Human interleukin-4 peptides and conjugates thereof
EP0550650B1 (en) Antagonists of human gamma interferon
AU4119085A (en) Antibodies to human interleukin-2 induced by synthetic polypeptides
US4652629A (en) Synthetic peptide-based anti-rabies compositions and methods
JPH083200A (ja) Ｈｔｌｖ−ｉｉｉ／ｌａｖウイルス関連ペプチドに対する抗体
EP0331100A1 (en) Anti-endothelin antibodies and their use
US6682896B1 (en) Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
US5869603A (en) Peptides representing eptiopic sites on r-IFN-β, antibodies thereto, and uses thereof
US6932968B1 (en) Erythropoietin (EPO) peptides and antibodies directed against these
US4707356A (en) Synthetic peptide-based anti-rabies compositions and methods
US5066593A (en) Synthetic peptide-based anti-rabies compositions and methods
JP3024987B2 (ja) 抗体、その製造法および用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20011029

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20021224

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20021224

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000